On November 12, 2025 in Salt Lake City, Spencer Cox — Governor of Utah — joined Kelvyn Cullimore of BioUtah to formally recognise Co‑Diagnostics, Inc. (Nasdaq: CODX) for its strategic move in forming a joint venture in the Kingdom of Saudi Arabia.
The Utah-based molecular diagnostics firm announced the establishment of CoMira Diagnostics, a new joint venture (JV) in Saudi Arabia, signalling an important step in its global growth.
Company Origins & Technology
Co-Diagnostics, Inc., incorporated in Utah, specialises in molecular diagnostics. The company designs, develops, manufactures and markets diagnostic technologies aimed at detecting or analysing nucleic acid molecules (DNA or RNA).
Its proprietary platform includes the Co-Dx™ PCR at-home and point-of-care platform (still subject to regulatory review and not yet for sale).
The Saudi Arabia Joint Venture & Global Expansion
JV Formation
The joint venture, CoMira Diagnostics, is formed in partnership with Arabian Eagle Manufacturing in the Kingdom of Saudi Arabia (KSA). Under this definitive agreement, Co-Diagnostics licences its intellectual property to CoMira, which will handle manufacturing, assembly, distribution and commercialization of Co-Dx technologies across KSA and up to 18 other Middle East & North Africa (MENA) countries.
Regional Scope
The Territory covered by the JV includes co-markets such as Bahrain, Iraq, Jordan, Kuwait, Lebanon, Oman, Palestine, Qatar, Syria, Turkey, United Arab Emirates, Yemen, Algeria, Egypt, Libya, Morocco, Sudan and Tunisia.
The move aligns with Saudi Arabia’s Vision 2030 objective of localising technology, diversifying industry, and advancing healthcare innovation.
Recognition by Utah Officials
Governor Spencer Cox expressed pride that a Utah-based company is now “building tools that help more patients around the world.” He emphasised how the expansion into the Middle East and North Africa reflects the strength of Utah’s life-sciences sector and the entrepreneurial spirit of its businesses.
Kelvyn Cullimore of BioUtah added that Co-Diagnostics’ recent definitive JV agreement with a Saudi partner “further confirms” its growing leadership and global presence — and that BioUtah is proud to count Co-Diagnostics among its elite members.
Why This Matters
- Global reach expansion: The joint venture opens a route for Co-Diagnostics to distribute its technologies across a broad MENA region, increasing market access outside the U.S.
- Technology localisation: Manufacturing and regulatory operations in KSA enhance the ability for on-ground production and faster regulatory pathways in the region.
- Healthcare impact: By localising molecular-diagnostics manufacturing, Co-Diagnostics potentially accelerates access to advanced testing and point-of-care diagnostics for patients across the Middle East & North Africa.
- Business strategy alignment: The move aligns with national industrial priorities (like KSA Vision 2030) which can lead to favourable regulatory and operational support.
Co-Diagnostics, Inc.’s formation of CoMira Diagnostics in Saudi Arabia marks a significant milestone in the company’s international growth story.
With strong backing from Utah officials and membership in BioUtah, the company is leveraging its patented molecular diagnostics platform to enter a wide territory in the Middle East & North Africa.
The strategic localisation of manufacturing and distribution not only serves business expansion but also strengthens healthcare accessibility in emerging markets. For a Utah-based diagnostics company, this step underscores how local innovation can make global impact.
